Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report

doi:10.7326/L20-0354

Case Reports

. 2020 Sep 15;173(6):499-501.

doi: 10.7326/L20-0354. Epub 2020 May 12.

Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report

Changsong Wang¹, Kai Kang², Yan Gao³, Ming Ye⁴, Xiuwen Lan⁵, Xueting Li⁵, Mingyan Zhao², Kaijiang Yu²

Affiliations

¹ The First Affiliated Hospital of Harbin Medical University and Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China (C.W.).
² The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China (K.K., M.Z., K.Y.).
³ The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China (Y.G.).
⁴ The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China (M.Y.).
⁵ Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China (X.L., X.L.).

PMID: 32422085
PMCID: PMC7224607
DOI: 10.7326/L20-0354

Case Reports

Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report

Changsong Wang et al. Ann Intern Med. 2020.

. 2020 Sep 15;173(6):499-501.

doi: 10.7326/L20-0354. Epub 2020 May 12.

Authors

Changsong Wang¹, Kai Kang², Yan Gao³, Ming Ye⁴, Xiuwen Lan⁵, Xueting Li⁵, Mingyan Zhao², Kaijiang Yu²

Affiliations

¹ The First Affiliated Hospital of Harbin Medical University and Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China (C.W.).
² The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China (K.K., M.Z., K.Y.).
³ The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China (Y.G.).
⁴ The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China (M.Y.).
⁵ Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China (X.L., X.L.).

PMID: 32422085
PMCID: PMC7224607
DOI: 10.7326/L20-0354

No abstract available

PubMed Disclaimer

Figures

See this image and copyright information in PMC

Cited by

Post-COVID-19 inflammatory syndrome manifesting as refractory status epilepticus.
Carroll E, Neumann H, Aguero-Rosenfeld ME, Lighter J, Czeisler BM, Melmed K, Lewis A. Carroll E, et al. Epilepsia. 2020 Oct;61(10):e135-e139. doi: 10.1111/epi.16683. Epub 2020 Sep 18. Epilepsia. 2020. PMID: 32944946 Free PMC article.
Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China.
Liu Y, Guo Y, Zhan H, Liu X, Li X, Cui J, Li H, Feng S, Cheng L, Li X, Guo S, Li Y. Liu Y, et al. BMC Infect Dis. 2024 Aug 9;24(1):809. doi: 10.1186/s12879-024-09652-y. BMC Infect Dis. 2024. PMID: 39123106 Free PMC article.
Cytokine levels in sputum, not serum, may be more helpful for indicating the damage in the lung and the prognosis of severe COVID-19 - A case series.
Wang C, Kang K, Lan X, Fei D, Wang Q, Li X, Chong Y, Gao Y, Wang H, Li X, Zhao M, Yu K. Wang C, et al. J Infect. 2021 Nov;83(5):e6-e9. doi: 10.1016/j.jinf.2021.08.026. Epub 2021 Aug 19. J Infect. 2021. PMID: 34419557 Free PMC article.
Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products.
Durkee-Shock J, Lazarski CA, Jensen-Wachspress MA, Zhang A, Son A, Kankate VV, Field NE, Webber K, Lang H, Conway SR, Hanley PJ, Bollard CM, Keller MD, Schwartz DM. Durkee-Shock J, et al. Mol Ther Methods Clin Dev. 2022 Jun 9;25:439-447. doi: 10.1016/j.omtm.2022.04.013. Epub 2022 Apr 29. Mol Ther Methods Clin Dev. 2022. PMID: 35506060 Free PMC article.
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B, Biray Avci C. Goker Bagca B, et al. Cytokine Growth Factor Rev. 2020 Aug;54:51-62. doi: 10.1016/j.cytogfr.2020.06.013. Epub 2020 Jun 20. Cytokine Growth Factor Rev. 2020. PMID: 32636055 Free PMC article. Review.

See all "Cited by" articles

References

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513. [PMID: 32007143] doi:10.1016/S0140-6736(20)30211-7. - PMC - PubMed
1. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420-422. [PMID: 32085846] doi:10.1016/S2213-2600(20)30076-X. - PMC - PubMed
1. Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr. 2014;26:43-9. [PMID: 24362408] doi:10.1097/MOP.0000000000000043. - PMC - PubMed
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. [PMID: 31986264] doi:10.1016/S0140-6736(20)30183-5. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources

[1] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513. [PMID: 32007143] doi:10.1016/S0140-6736(20)30211-7. - PMC - PubMed

[2] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513. [PMID: 32007143] doi:10.1016/S0140-6736(20)30211-7. - PMC - PubMed

[3] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420-422. [PMID: 32085846] doi:10.1016/S2213-2600(20)30076-X. - PMC - PubMed

[4] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420-422. [PMID: 32085846] doi:10.1016/S2213-2600(20)30076-X. - PMC - PubMed

[5] Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr. 2014;26:43-9. [PMID: 24362408] doi:10.1097/MOP.0000000000000043. - PMC - PubMed

[6] Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr. 2014;26:43-9. [PMID: 24362408] doi:10.1097/MOP.0000000000000043. - PMC - PubMed

[7] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. [PMID: 31986264] doi:10.1016/S0140-6736(20)30183-5. - PMC - PubMed

[8] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. [PMID: 31986264] doi:10.1016/S0140-6736(20)30183-5. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report

Affiliations

Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report

Authors

Affiliations

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources